Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.
A nonsurgical treatment strategy employing chemoradiotherapy is feasible for patients with early rectal cancer, a phase 3 trial suggests.
Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.
Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
Monitoring of ctDNA may be useful for early response assessment in patients with anal cancer receiving chemoradiation, a study suggests.
Combination botensilimab and balstilimab elicits durable responses in refractory, metastatic, microsatellite-stable colorectal cancer, a phase 1 trial suggests.
NALIRIFOX outperformed treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer in the NAPOLI-3 trial.
Nanvuranlat improved progression-free survival, compared with placebo, in heavily pretreated patients with advanced biliary tract cancer.
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.
Long-term results confirm that 4 courses of S-1 chemotherapy is inferior to the standard 8 courses in patients with stage II gastric cancer.
Patients with gastric cancer or dysplasia who underwent endoscopic submucosal dissection at very low-volume centers had a higher risk of adverse outcomes.
Combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/GEJ cancer, a phase 3 study suggests.
Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.
Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.
Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.
The COVID-19 pandemic delayed the diagnosis of gastric, esophageal, or GEJ cancer but did not impact survival in a single-center study.